Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Olivier Antoine M. Charmeil

CEOOlivier Antoine M. Charmeil

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

113.14B

Market cap113.14B

Price-Earnings ratio

19.81

Price-Earnings ratio19.81

Dividend yield

3.35%

Dividend yield3.35%

Average volume

4.54M

Average volume4.54M

High today

$46.87

High today$46.87

Low today

$46.03

Low today$46.03

Open price

$46.74

Open price$46.74

Volume

4.36M

Volume4.36M

52 Week high

$60.12

52 Week high$60.12

52 Week low

$44.62

52 Week low$44.62

SNY News

TipRanks 11h

Sanofi Wins FDA Nod for Dupixent as First Targeted Treatment for Allergic Fungal Rhinosinusitis

Sanofi ( (SNY) ) has shared an update. On February 24, 2026, Sanofi and Regeneron secured U.S. FDA priority-review approval for Dupixent as the first and only...

Nasdaq 2d

Sanofi: Rilzabrutinib Granted Orphan Drug Designation In Japan For IgG4-related Disease

(RTTNews) - Sanofi (SNY, SAN.PA) announced the Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to rilzabrutinib, an oral, re...

TipRanks 2d

Sanofi’s Blueprint Medicines presents data on Ayvakit ay AAAAI

Blueprint Medicines, a Sanofi (SNY) company, announced Ayvakit data showing clinically meaningful outcomes and a well-tolerated long-term safety profile in pati...

Analyst ratings

67%

of 6 ratings

Buy

66.7%

Hold

33.3%

Sell

More SNY News

Simply Wall St 4d

Recursion’s First Clinical Signal And Sanofi Milestone Test AI Drug Thesis

Recursion Pharmaceuticals reported its first positive clinical proof-of-concept for REC-4881 in familial adenomatous polyposis. The company hit a fifth collabo...

TipRanks 4d

Regeneron, Sanofi announces EMA for CHMP adopted positive opinion for Dupixent

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, ado...

TipRanks 5d

Novavax sees FY26 adjusted total revenue $230M-$270M

Novavax (NVAX) transitioned lead commercial responsibility of Nuvaxovid beginning with the 2025-2026 COVID-19 vaccination season to Sanofi (SNY) for select mark...

The Motley Fool 6d

Recursion Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Wednesday, Feb. 25, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Najat Khan Chief Financial Officer — Ben Taylo...

Nasdaq 7d

FDA Approves Sanofi And Regeneron's Dupixent As First Medicine For Allergic Fungal Rhinosinusitis

(RTTNews) - Sanofi (SNY, SAN.PA) said FDA has approved Dupixent or dupilumab for the treatment of adult and pediatric patients aged 6 years and older with aller...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.